IP Library › Granted Patent US 12,290,538
Granted Patent B2
US 12,290,538 · App. 17/628,339 · Granted May 6, 2025

Methods and products for treatment of gastrointestinal disorders

Inventors: Mark Smith (Somerville, MA); Anh-Thu Elaine Vo (Somerville, MA); Rotem Sadovsky (Somerville, MA); John Henske (Somerville, MA); Ylaine Gerardin (Somerville, MA); Sonia Timberlake (Somerville, MA); Cosmas Giallourakis (Cambridge, MA); Ewan Taylor (San Diego, CA)
Assignees: Finch Therapeutics Holdings LLC; Millennium Pharmaceuticals, Inc.
A61K35/741A61P1/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,538
App. No.
17/628,339
Granted
May 6, 2025
Kind
B2
Abstract

Described herein are compositions and methods for the delivery of microbial therapeutics useful for the treatment of disorders related to intestinal dysbiosis.

Claims (25)

1. A method of treating inflammatory bowel disease (IBD) in a subject with IBD in need thereof, the method comprising administering to the subject a plurality of bacterial isolates, wherein the plurality of bacterial isolates comprises Bacteroides stercoris and Bacteroides cellulosilyticus , and at least one of Bacteroides uniformis, Subdoligranulum variabile, Anaerostipes hadrus, Odoribacter splanchnicus, Roseburia faecis, Faecalibacterium prausnitzii, Akkermansia muciniphila, Alistipes shahii , and Eubacterium rectale , wherein the Bacteroides stercoris comprises a 16S ribosomal ribonucleic acid (rRNA) sequence that has at least 95% sequence identity with the nucleotide sequence of SEQ ID NO: 13.

2. The method of claim 1 , wherein at least two of the plurality of bacterial isolates are isolated from a stool of different human donors.

3. The method of claim 1 , wherein the plurality of bacterial isolates comprises at least two of Bacteroides uniformis, Odoribacter splanchnicus, Roseburia faecis, Anaerostipes hadrus, Faecalibacterium prausnitzii, Subdoligranulum variabile, Akkermansia muciniphila, Alistipes shahii , and Eubacterium rectale.

4. The method of claim 1 , wherein the plurality of bacterial isolates comprises at least three of Bacteroides uniformis, Odoribacter splanchnicus, Roseburia faecis, Anaerostipes hadrus, Faecalibacterium prausnitzii, Subdoligranulum variabile, Akkermansia muciniphila, Alistipes shahii , and Eubacterium rectale.

5. The method of claim 1 , wherein the plurality of bacterial isolates comprises at least four of Bacteroides uniformis, Odoribacter splanchnicus, Roseburia faecis, Anaerostipes hadrus, Faecalibacterium prausnitzii, Subdoligranulum variabile, Akkermansia muciniphila, Alistipes shahii , and Eubacterium rectale.

6. The method of claim 1 , wherein the plurality of bacterial isolates comprises at least five of Bacteroides uniformis, Odoribacter splanchnicus, Roseburia faecis, Anaerostipes hadrus, Faecalibacterium prausnitzii, Subdoligranulum variabile, Akkermansia muciniphila, Alistipes shahii , and Eubacterium rectale.

7. The method of claim 1 , wherein the plurality of bacterial isolates comprises at least six of Bacteroides uniformis, Odoribacter splanchnicus, Roseburia faecis, Anaerostipes hadrus, Faecalibacterium prausnitzii, Subdoligranulum variabile, Akkermansia muciniphila, Alistipes shahii , and Eubacterium rectale.

8. The method of claim 1 , wherein the plurality of bacterial isolates comprises at least seven of Bacteroides uniformis, Odoribacter splanchnicus, Roseburia faecis, Anaerostipes hadrus, Faecalibacterium prausnitzii, Subdoligranulum variabile, Akkermansia muciniphila, Alistipes shahii , and Eubacterium rectale.

9. The method of claim 1 , wherein the plurality of bacterial isolates comprises a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequences selected from SEQ ID NOs: 1, 2, 3, 7, 8, 11, 14, 18, 19, 20, 22 and 23.

10. The method of claim 1 , wherein the plurality of bacterial isolates comprises:

(a) a 16S rRNA sequence that has a least 95% sequence identity with nucleotide sequence of SEQ ID NOs: 1 and/or 7,

(b) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NO: 2,

(c) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NO: 3,

(d) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NO: 8,

(e) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NO: 11

(f) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NO: 14,

(g) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NO: 18,

(h) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NO: 19,

(i) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NO: 20, and/or

(j) a 16S rRNA sequence that has at least 95% sequence identity with nucleotide sequence of SEQ ID NOs: 22 and/or 23.

11. The method of claim 1 , wherein the plurality of bacterial isolates comprises at least two bacterial isolates comprising Faecalibacterium prausnitzii , wherein at least two bacterial isolates comprise different 16S rRNA sequences.

12. The method of claim 11 , wherein the at least two bacterial isolates comprising Faecalibacterium prausnitzii comprise 16S rRNA sequences that have at least 95% sequence identity with nucleotide sequences of SEQ ID NOs: 1 and/or 7.

13. The method of claim 11 , wherein at least two bacterial isolates comprising Faecalibacterium prausnitzii are isolated from a stool of different human donors.

14. The method of claim 1 , wherein the plurality of bacterial isolates comprises lyophilized bacteria.

15. The method of claim 1 , wherein the plurality of bacterial isolates does not include Escherichia coli.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: SADOVSKY, ROTEM GURA; VO, ANH-THU ELAINE; HENSKE, JOHN; GERARDIN, YLAINE; SMITH, MARK; TIMBERLAKE, SONIA
To: FINCH THERAPEUTICS, INC.
Reel/Frame 059812/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: GIALLOURAKIS, COSMAS; TAYLOR, EWAN
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 059812/0557 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: FINCH THERAPEUTICS, INC.
To: CRESTOVO HOLDINGS LLC
Reel/Frame 059812/0565 →
CHANGE OF NAME Recorded May 4, 2022
From: CRESTOVO HOLDINGS LLC
To: FINCH THERAPEUTICS HOLDINGS LLC
Reel/Frame 059853/0892 →
Continuity (3)
Provisional Application 63001888 · Mar 30, 2020
Provisional Application 62876350 · Jul 19, 2019
Related Publication 20220257673A1 · Aug 18, 2022
References Cited (400)
US 3192116A · Möse et al. · 1965 [cited by applicant]
US 3320130A · Henry · 1967 [cited by applicant]
US 3713836A · Carlsson · 1973 [cited by applicant]
US 4098728A · Rosenblatt · 1978 [cited by applicant]
US 4196564A · Bodenmann et al. · 1980 [cited by applicant]
US 4196565A · Bodenmann et al. · 1980 [cited by applicant]
US 4247006A · Bodenmann et al. · 1981 [cited by applicant]
US 4250997A · Bodenmann et al. · 1981 [cited by applicant]
US 4268265A · Von Wattenwyl · 1981 [cited by applicant]
US 4309782A · Paulin · 1982 [cited by applicant]
US 4332790A · Sozzi et al. · 1982 [cited by applicant]
US 4335107A · Snoeyenbos et al. · 1982 [cited by applicant]
US 4394377A · Spires · 1983 [cited by applicant]
US 4452779A · Cockerill · 1984 [cited by applicant]
US 4536409A · Farrell et al. · 1985 [cited by applicant]
US 4537776A · Cooper · 1985 [cited by applicant]
US 4657762A · Mikkola et al. · 1987 [cited by applicant]
US 4710379A · Kawai et al. · 1987 [cited by applicant]
US 4892731A · Arai et al. · 1990 [cited by applicant]
US 4975286A · Hechter · 1990 [cited by applicant]
US 5213807A · Chemburkar et al. · 1993 [cited by applicant]
US 5266315A · Taguchi et al. · 1993 [cited by applicant]
US 5317849A · Sauter · 1994 [cited by applicant]
US 5443826A · Borody · 1995 [cited by applicant]
US 5599795A · McCann et al. · 1997 [cited by applicant]
US 5728380A · Allen et al. · 1998 [cited by applicant]
US 5800821A · Acheson et al. · 1998 [cited by applicant]
US 5837238A · Casas et al. · 1998 [cited by applicant]
US 5858356A · Wolf et al. · 1999 [cited by applicant]
US 5902578A · Halpin-Dohnalek et al. · 1999 [cited by applicant]
US 5902743A · Luchansky et al. · 1999 [cited by applicant]
US 6087386A · Chen et al. · 2000 [cited by applicant]
US 6162464A · Jacob et al. · 2000 [cited by applicant]
US 6245740B1 · Goldenberg et al. · 2001 [cited by applicant]
US 6284274B1 · Merrill et al. · 2001 [cited by applicant]
US 6428783B1 · Khachatrian et al. · 2002 [cited by applicant]
US 6479051B1 · Bruce et al. · 2002 [cited by applicant]
US 6514531B1 · Alaux et al. · 2003 [cited by applicant]
US 6572892B1 · Ioulalen et al. · 2003 [cited by applicant]
US 6645530B1 · Borody · 2003 [cited by applicant]
US 6649397B1 · Nakamura · 2003 [cited by applicant]
US 6756032B1 · Tepper et al. · 2004 [cited by applicant]
US 6926907B2 · Plachetka · 2005 [cited by applicant]
US 6979674B1 · Goldenberg et al. · 2005 [cited by applicant]
US 6984513B2 · Brown et al. · 2006 [cited by applicant]
US 7018629B2 · Jacob et al. · 2006 [cited by applicant]
US 7374753B1 · Farmer et al. · 2008 [cited by applicant]
US 7541091B2 · Sisson et al. · 2009 [cited by applicant]
US 7712634B2 · MacMichael et al. · 2010 [cited by applicant]
US 7749509B2 · Cobb et al. · 2010 [cited by applicant]
US 7763276B1 · Shodai et al. · 2010 [cited by applicant]
US 7799328B2 · Hublot et al. · 2010 [cited by applicant]
US 7799341B2 · Porzio et al. · 2010 [cited by applicant]
US 7815956B2 · Lee et al. · 2010 [cited by applicant]
US 7845475B2 · Shiraishi et al. · 2010 [cited by applicant]
US 7888062B1 · Garner et al. · 2011 [cited by applicant]
US 7998510B2 · Caswell · 2011 [cited by applicant]
US 8074835B2 · MacMichael et al. · 2011 [cited by applicant]
US 8168171B2 · Mogna et al. · 2012 [cited by applicant]
US 8398912B2 · Goossens et al. · 2013 [cited by applicant]
US 8440224B2 · Clarke et al. · 2013 [cited by applicant]
US 8460648B2 · Borody · 2013 [cited by applicant]
US 8535713B2 · Coulter · 2013 [cited by applicant]
US 8557294B2 · Scott et al. · 2013 [cited by applicant]
US 8586029B2 · Kasper et al. · 2013 [cited by applicant]
US 8637297B2 · Vieites Fernandez et al. · 2014 [cited by applicant]
US 8646591B2 · De Ruijter et al. · 2014 [cited by applicant]
US 8658153B2 · Daube et al. · 2014 [cited by applicant]
US 8739812B2 · Brandon-Jones et al. · 2014 [cited by applicant]
US 8771673B2 · Cobb et al. · 2014 [cited by applicant]
US 8810259B2 · Herrmann et al. · 2014 [cited by applicant]
US 8852631B2 · Cade et al. · 2014 [cited by applicant]
US 8911777B2 · Coulter · 2014 [cited by applicant]
US 8911788B2 · Ioualalen et al. · 2014 [cited by applicant]
US 9040036B2 · Borody · 2015 [cited by applicant]
US 9050358B2 · Borody · 2015 [cited by applicant]
US 9308226B2 · Borody · 2016 [cited by applicant]
US 9320763B2 · Borody · 2016 [cited by applicant]
US 9408872B2 · Borody · 2016 [cited by applicant]
US 9468658B2 · Borody · 2016 [cited by applicant]
US 9572841B2 · Borody · 2017 [cited by applicant]
US 9572842B2 · Borody · 2017 [cited by applicant]
US 9610308B2 · Borody · 2017 [cited by applicant]
US 9623056B2 · Borody · 2017 [cited by applicant]
US 9682108B2 · Borody · 2017 [cited by applicant]
US 9719144B2 · Krajmalnik-Brown et al. · 2017 [cited by applicant]
US 9737574B2 · Borody · 2017 [cited by applicant]
US 9789140B2 · Borody · 2017 [cited by applicant]
US 9867858B2 · Borody · 2018 [cited by applicant]
US 9901603B2 · Borody · 2018 [cited by applicant]
US 9901604B2 · Borody · 2018 [cited by applicant]
US 9962413B2 · Borody · 2018 [cited by applicant]
US 9962414B2 · Borody · 2018 [cited by applicant]
US 9968638B2 · Sadowsky et al. · 2018 [cited by applicant]
US 10022406B2 · Borody · 2018 [cited by applicant]
US 10028980B2 · Sadowsky et al. · 2018 [cited by applicant]
US 10064899B1 · Borody · 2018 [cited by applicant]
US 10092601B2 · Borody · 2018 [cited by applicant]
US 10195235B2 · Borody · 2019 [cited by applicant]
US 10251914B2 · Sadowsky et al. · 2019 [cited by applicant]
US 10278997B2 · Borody · 2019 [cited by applicant]
US 10286011B2 · Sadowsky et al. · 2019 [cited by applicant]
US 10286012B2 · Sadowsky et al. · 2019 [cited by applicant]
US 10328107B2 · Borody · 2019 [cited by applicant]
US 10369175B2 · Borody · 2019 [cited by applicant]
US 10463702B2 · Borody · 2019 [cited by applicant]
US 20010014322A1 · Chen et al. · 2001 [cited by applicant]
US 20020013270A1 · Bolte · 2002 [cited by applicant]
US 20020022019A1 · Laulund · 2002 [cited by applicant]
US 20020039599A1 · Lin et al. · 2002 [cited by applicant]
US 20030092163A1 · Collins et al. · 2003 [cited by applicant]
US 20030092724A1 · Kao et al. · 2003 [cited by applicant]
US 20030147858A1 · Renaud et al. · 2003 [cited by applicant]
US 20040062757A1 · Finegold · 2004 [cited by applicant]
US 20040167062A1 · Bolte · 2004 [cited by applicant]
US 20040170617A1 · Finegold · 2004 [cited by applicant]
US 20040223956A1 · Naidu et al. · 2004 [cited by applicant]
US 20060001896A1 · Sakamoto · 2006 [cited by applicant]
US 20060076536A1 · Barshied · 2006 [cited by applicant]
US 20060099197A1 · Farmer · 2006 [cited by applicant]
US 20060115465A1 · Macfarlane et al. · 2006 [cited by applicant]
US 20060177424A1 · Cobb et al. · 2006 [cited by applicant]
US 20060275223A1 · Burr · 2006 [cited by applicant]
US 20070059296A1 · Chen · 2007 [cited by applicant]
US 20070292523A1 · Moodley et al. · 2007 [cited by applicant]
US 20080020018A1 · Moodley et al. · 2008 [cited by applicant]
US 20080113031A1 · Moodley et al. · 2008 [cited by applicant]
US 20080254009A1 · Finegold · 2008 [cited by applicant]
US 20080299197A1 · Toneguzzo et al. · 2008 [cited by applicant]
US 20100112003A1 · Collins et al. · 2010 [cited by applicant]
US 20100178349A1 · Kolter et al. · 2010 [cited by applicant]
US 20100178413A1 · Gorris · 2010 [cited by applicant]
US 20100184785A1 · Kolter et al. · 2010 [cited by applicant]
US 20100203120A1 · Coulter · 2010 [cited by applicant]
US 20100222311A1 · Thommes et al. · 2010 [cited by applicant]
US 20100226866A1 · Yamashiro et al. · 2010 [cited by applicant]
US 20100233278A1 · Ookawa et al. · 2010 [cited by applicant]
US 20100239667A1 · Hemmingsen et al. · 2010 [cited by applicant]
US 20100247489A1 · Saur-Brosch · 2010 [cited by applicant]
US 20100247665A1 · Takahashi · 2010 [cited by applicant]
US 20100255087A1 · Coulter · 2010 [cited by applicant]
US 20100255231A1 · Chau et al. · 2010 [cited by applicant]
US 20100255307A1 · Gonze et al. · 2010 [cited by applicant]
US 20100278930A1 · Okumura et al. · 2010 [cited by applicant]
US 20100285164A1 · Schaible et al. · 2010 [cited by applicant]
US 20100289164A1 · Porzio et al. · 2010 [cited by applicant]
US 20100297031A1 · Úbeda Pérez et al. · 2010 [cited by applicant]
US 20100297221A1 · Coulter · 2010 [cited by applicant]
US 20110008554A1 · Chen et al. · 2011 [cited by applicant]
US 20110045222A1 · Peters · 2011 [cited by applicant]
US 20110052645A1 · Coulter · 2011 [cited by applicant]
US 20110081320A1 · Westall et al. · 2011 [cited by applicant]
US 20110091431A1 · Olmstead · 2011 [cited by applicant]
US 20110200570A1 · Mosbaugh et al. · 2011 [cited by applicant]
US 20110218216A1 · Vivek et al. · 2011 [cited by applicant]
US 20120020941A1 · Wacklin et al. · 2012 [cited by applicant]
US 20120039853A1 · Corveleyn et al. · 2012 [cited by applicant]
US 20120064133A1 · Chauhan et al. · 2012 [cited by applicant]
US 20120087895A1 · Mazmanian et al. · 2012 [cited by applicant]
US 20120129773A1 · Geier et al. · 2012 [cited by applicant]
US 20120141531A1 · Coulter et al. · 2012 [cited by applicant]
US 20120141585A1 · Coulter et al. · 2012 [cited by applicant]
US 20120183612A1 · Brögmann et al. · 2012 [cited by applicant]
US 20120252775A1 · Finegold · 2012 [cited by applicant]
US 20130022622A1 · Ben-Ari et al. · 2013 [cited by applicant]
US 20130045274A1 · Hlavka · 2013 [cited by applicant]
US 20130184290A1 · Padval et al. · 2013 [cited by applicant]
US 20130195804A1 · Borody · 2013 [cited by applicant]
US 20130243873A1 · Aversa et al. · 2013 [cited by applicant]
US 20130259899A1 · Allen-Vercoe et al. · 2013 [cited by applicant]
US 20130287842A1 · Cade et al. · 2013 [cited by applicant]
US 20130295188A1 · Cade et al. · 2013 [cited by applicant]
US 20130307962A1 · Humphries et al. · 2013 [cited by applicant]
US 20130316394A1 · Stimpson · 2013 [cited by applicant]
US 20130330411A1 · Coulter · 2013 [cited by applicant]
US 20140017313A1 · Coulter et al. · 2014 [cited by applicant]
US 20140065132A1 · Hsiao et al. · 2014 [cited by applicant]
US 20140086877A1 · Hlavka · 2014 [cited by applicant]
US 20140088202A1 · Cade et al. · 2014 [cited by applicant]
US 20140147417A1 · Sadowsky et al. · 2014 [cited by applicant]
US 20140147425A1 · Henn et al. · 2014 [cited by applicant]
US 20140227357A1 · Vertommen et al. · 2014 [cited by applicant]
US 20140234260A1 · Borody · 2014 [cited by applicant]
US 20140234418A1 · Coulter et al. · 2014 [cited by applicant]
US 20140255351A1 · Berstad et al. · 2014 [cited by applicant]
US 20140302132A1 · Brown · 2014 [cited by applicant]
US 20140328803A1 · Mckenzie et al. · 2014 [cited by applicant]
US 20140341921A1 · Honda et al. · 2014 [cited by applicant]
US 20140342438A1 · Allen-Vercoe et al. · 2014 [cited by applicant]
US 20140363397A1 · Allen-Vercoe et al. · 2014 [cited by applicant]
US 20140363398A1 · Jones et al. · 2014 [cited by applicant]
US 20150044173A1 · Jones et al. · 2015 [cited by applicant]
US 20150050246A1 · Jones et al. · 2015 [cited by applicant]
US 20150093360A1 · McKenzie et al. · 2015 [cited by applicant]
US 20150143557A1 · Honda et al. · 2015 [cited by applicant]
US 20150152484A1 · Krajmalnik-Brown et al. · 2015 [cited by applicant]
US 20150190435A1 · Henn et al. · 2015 [cited by applicant]
US 20150224152A1 · Littman et al. · 2015 [cited by applicant]
US 20150238544A1 · Jones et al. · 2015 [cited by applicant]
US 20150238545A1 · Borody · 2015 [cited by applicant]
US 20150238546A1 · Borody · 2015 [cited by applicant]
US 20150293072A1 · Geigenmuller et al. · 2015 [cited by applicant]
US 20150297642A1 · Borody · 2015 [cited by applicant]
US 20150306144A1 · Borody · 2015 [cited by applicant]
US 20150306155A1 · Borody · 2015 [cited by applicant]
US 20150306156A1 · Borody · 2015 [cited by applicant]
US 20150374761A1 · Sadowsky et al. · 2015 [cited by applicant]
US 20160040215A1 · Henn · 2016 [cited by examiner]
US 20160089363A1 · Borody · 2016 [cited by applicant]
US 20160091480A1 · Geigenmuller et al. · 2016 [cited by applicant]
US 20160143962A1 · Berry et al. · 2016 [cited by applicant]
US 20160151429A1 · Borody · 2016 [cited by applicant]
US 20160151431A1 · Borody · 2016 [cited by applicant]
US 20160151432A1 · Borody · 2016 [cited by applicant]
US 20160151433A1 · Borody · 2016 [cited by applicant]
US 20160158294A1 · Von Maltzahn et al. · 2016 [cited by applicant]
US 20160243175A1 · Bushman et al. · 2016 [cited by applicant]
US 20160279178A1 · Borody · 2016 [cited by applicant]
US 20160279179A1 · Borody · 2016 [cited by applicant]
US 20160339065A1 · Adams et al. · 2016 [cited by applicant]
US 20170165302A1 · Henn et al. · 2017 [cited by applicant]
US 20170216378A1 · Honda et al. · 2017 [cited by applicant]
US 20170246220A1 · Sato et al. · 2017 [cited by applicant]
US 20170319627A1 · Sadowsky et al. · 2017 [cited by applicant]
US 20170348360A1 · Borody · 2017 [cited by applicant]
US 20180110810A1 · Sadowsky et al. · 2018 [cited by applicant]
US 20180153943A1 · Borody · 2018 [cited by applicant]
US 20180169153A1 · Berry et al. · 2018 [cited by applicant]
US 20180200310A1 · McKenzie et al. · 2018 [cited by applicant]
US 20180256652A1 · Borody · 2018 [cited by applicant]
US 20180353554A1 · Henn et al. · 2018 [cited by applicant]
US 20190015460A1 · Borody · 2019 [cited by applicant]
US 20190015461A1 · Borody · 2019 [cited by applicant]
US 20190015462A1 · Borody · 2019 [cited by applicant]
US 20190046589A1 · Borody · 2019 [cited by applicant]
US 20190070225A1 · Strandwitz et al. · 2019 [cited by applicant]
US 20190134106A1 · Borody · 2019 [cited by applicant]
US 20190134144A1 · Adams et al. · 2019 [cited by applicant]
US 20190144923A1 · Krajmalnik-Brown et al. · 2019 [cited by applicant]
US 20190175665A1 · Borody · 2019 [cited by applicant]
US 20190216860A1 · Borody · 2019 [cited by applicant]
US 20190247445A1 · Hamilton et al. · 2019 [cited by applicant]
US 20190290704A1 · Borody · 2019 [cited by applicant]
US 20190328825A1 · Adams et al. · 2019 [cited by applicant]
US 20190343897A1 · Borody · 2019 [cited by applicant]
US 20190358274A1 · Adams et al. · 2019 [cited by applicant]
AU 2001276160B2 · 2007 [cited by applicant]
CA 1333564 · 1994 [cited by applicant]
CA 2391422A1 · 2004 [cited by applicant]
CN 1561387A · 2005 [cited by applicant]
CN 101496819A · 2009 [cited by applicant]
CN 201441672U · 2010 [cited by applicant]
DE 2134179A1 · 1973 [cited by applicant]
EP 0303246A2 · 1989 [cited by applicant]
EP 0303426A2 · 1989 [cited by applicant]
EP 0456418B1 · 1991 [cited by applicant]
EP 0433299B1 · 1998 [cited by applicant]
EP 1514572A2 · 2005 [cited by applicant]
EP 1514572A3 · 2006 [cited by applicant]
EP 1800688A1 · 2007 [cited by applicant]
EP 1514572B1 · 2008 [cited by applicant]
EP 2823822B1 · 2016 [cited by applicant]
EP 3424515A2 · 2019 [cited by applicant]
EP 3610881A1 · 2020 [cited by applicant]
FR 1275M · 1962 [cited by applicant]
FR 2427M · 1964 [cited by applicant]
FR 2828M · 1964 [cited by applicant]
FR 5528M · 1967 [cited by applicant]
FR 2244464A1 · 1975 [cited by applicant]
GB 1271674A · 1972 [cited by applicant]
JP 64067192 · 1989 [cited by applicant]
JP H05306221A · 1993 [cited by applicant]
JP H07242539A · 1995 [cited by applicant]
JP H07242557A · 1995 [cited by applicant]
JP 3144556B2 · 2001 [cited by applicant]
JP 2004501095 · 2004 [cited by applicant]
JP 2005118544A · 2005 [cited by applicant]
JP 2008106066 · 2008 [cited by applicant]
JP 2010513359 · 2010 [cited by applicant]
JP 2010520234A · 2010 [cited by applicant]
JP 2014507481A · 2014 [cited by applicant]
JP 2015520176A · 2015 [cited by applicant]
JP 2016519664A · 2016 [cited by applicant]
JP 2016155880A · 2016 [cited by applicant]
JP 2016509003A5 · 2017 [cited by applicant]
JP 2017514872A · 2017 [cited by applicant]
KR 100913405B1 · 2009 [cited by applicant]
WO WO9001335A1 · 1990 [cited by applicant]
WO WO9533046A1 · 1995 [cited by applicant]
WO WO9611014A1 · 1996 [cited by applicant]
WO WO9813068A1 · 1998 [cited by applicant]
WO WO0007571A2 · 2000 [cited by applicant]
WO WO00015760A1 · 2000 [cited by applicant]
WO WO0042168A2 · 2000 [cited by applicant]
WO WO0207741A1 · 2002 [cited by applicant]
WO WO03033681A2 · 2003 [cited by applicant]
WO WO2005017095A2 · 2005 [cited by applicant]
WO WO2006127355A2 · 2006 [cited by applicant]
WO WO2007122374A2 · 2007 [cited by applicant]
WO WO2008077614A2 · 2008 [cited by applicant]
WO WO2008105715A2 · 2008 [cited by applicant]
WO WO2008117266A2 · 2008 [cited by applicant]
WO WO2008117267A2 · 2008 [cited by applicant]
WO WO2008135090A1 · 2008 [cited by applicant]
WO WO2008077614A3 · 2009 [cited by applicant]
WO WO2009024429A2 · 2009 [cited by applicant]
WO WO2009026306A2 · 2009 [cited by applicant]
WO WO2009055362A1 · 2009 [cited by applicant]
WO WO2010036876A2 · 2010 [cited by applicant]
WO WO2010040020A1 · 2010 [cited by applicant]
WO WO2011033310A1 · 2011 [cited by applicant]
WO WO2011110347A2 · 2011 [cited by applicant]
WO WO2011151941A1 · 2011 [cited by applicant]
WO WO2011152566A2 · 2011 [cited by applicant]
WO WO2012013861A2 · 2012 [cited by applicant]
WO WO2012016287A2 · 2012 [cited by applicant]
WO WO2012016287A3 · 2012 [cited by applicant]
WO WO2012045150A1 · 2012 [cited by applicant]
WO WO2012122478A1 · 2012 [cited by applicant]
WO WO2012142605A1 · 2012 [cited by applicant]
WO WO2013037067A1 · 2013 [cited by applicant]
WO WO2013037068A1 · 2013 [cited by applicant]
WO WO2013053836A1 · 2013 [cited by applicant]
WO WO2013090825A1 · 2013 [cited by applicant]
WO WO2013176774A1 · 2013 [cited by applicant]
WO WO2014036182A2 · 2014 [cited by applicant]
WO WO2014070014A1 · 2014 [cited by applicant]
WO WO2014078911A1 · 2014 [cited by applicant]
WO WO2014152338A1 · 2014 [cited by applicant]
WO WO2014152484A1 · 2014 [cited by applicant]
WO WO2015006355A2 · 2015 [cited by applicant]
WO WO2015051323A1 · 2015 [cited by applicant]
WO WO2015077794A1 · 2015 [cited by applicant]
WO WO2015095241A2 · 2015 [cited by applicant]
WO WO2015124637A1 · 2015 [cited by applicant]
WO WO2016133450A1 · 2016 [cited by applicant]
WO WO2016183577A1 · 2016 [cited by applicant]
WO WO2016191356A1 · 2016 [cited by applicant]
WO WO2017075098A1 · 2017 [cited by applicant]
WO WO2017091783A2 · 2017 [cited by applicant]
WO WO2017134240 · 2017 [cited by applicant]
WO WO2017152137A2 · 2017 [cited by applicant]
WO WO2017210428A1 · 2017 [cited by applicant]
WO WO2018006088A1 · 2018 [cited by applicant]
WO WO2018026913A1 · 2018 [cited by applicant]
WO WO2018057914 · 2018 [cited by applicant]
WO WO2018075886 · 2018 [cited by applicant]
WO WO2018187272 · 2018 [cited by applicant]
WO WO2018187272A1 · 2018 [cited by applicant]
WO WO2018187467A1 · 2018 [cited by applicant]
WO WO2019032572 · 2019 [cited by applicant]
WO WO2019032572A1 · 2019 [cited by applicant]
WO WO2019032573 · 2019 [cited by applicant]
WO WO2019032573A1 · 2019 [cited by applicant]
WO WO2019032575A1 · 2019 [cited by applicant]
WO WO2019041141A1 · 2019 [cited by applicant]
WO WO2019051380A1 · 2019 [cited by applicant]
WO WO2019075344A1 · 2019 [cited by applicant]
WO WO2019165285A1 · 2019 [cited by applicant]
Farraye et al. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease, 2017, American Journal of Gastroenterology, 112-241 (Year: 2017). [cited by examiner]
Panes et al.Improving quality of care in inflammatory bowel disease: What changes can be made today< 2014, Journal of Crohn's and Colitis, 8: 919-926 (Year: 2014). [cited by examiner]
Center for Disease Control (Inflammatory Bowel Disease (IBD), What Is It? 2018 https://www.cdc.gov/ibd/features/inflammatory-bowel-disease/index.html Last accessed Mar. 13, 2023 (Year: 2018). [cited by examiner]
Mayo Foundation for Medical Education and Research. Inflammatory Bowel Disease (IBD) Copyright 1998-2024. https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/symptoms-causes/syc-20353315 Last acces… [cited by examiner]
Encyclopedia.com. Disease Prevention. 2019. https://www.encyclopedia.com/education/encyclopedias-almanacs-transcripts-and-maps/disease-prevention Last accessed Mar. 19, 2024 (Year: 2019). [cited by examiner]
Martin-Dejardin, et al., “A way to follow the viability of encapsulated Bifidobacterium bifidum subjected to a freeze-drying process in order to target the colon: Interest of flow cytometry,” European Journal of Pharmac… [cited by applicant]
Maslowski, et al., “Diet, gut microbiota and immune responses,” Nat Immunol., 12(1):5-9 (2011). [cited by applicant]
McDonald, et al., “An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile,” N Engl J Med., 353(23):2433-41 (2005). [cited by applicant]
McDonald, et al., “Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996-2003” Emerg. Infect. Dis, 12(3):409-415 (2006). [cited by applicant]
McFarland, et al., “Breaking the Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium difficile Disease,” Am. J. Gastroenterol., 97(7):1769-1775 (2002). [cited by applicant]
McFarland, et al., “Implications of the changing face of Clostridium difficile disease for health care practitioners,” Am J Infect Control., 35(4):237-253 (2007). [cited by applicant]
McFarland, et al., “Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease,” Am J Gastroenterol., 101(4):812-22 (2006). [cited by applicant]
McFarland, et al., “Nosocomial Acquisition of Clostridium Difficile Infection,” N Engl J Med., 320(4):204-210 (1989). [cited by applicant]
McFarland, et al., “Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics,” Infect Control Hosp Epidemiol., 20(1):43-50 (1999). [cited by applicant]
McFarland, et al., “Renewed interest in a difficult disease: Clostridium difficile infections—epidemiology and current treatment strategies,” Curr Opin Gastroenterol., 25(1):24-35 (2008). [cited by applicant]
Meadows, “Gut Bacteria May Override Genetic Protections against Diabetes,” PLOS Biology, 9(12):e1001215 (2011). [cited by applicant]
Miller, et al., “Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality,” Clin Infect Dis., 50(2):194-201 (2010). [cited by applicant]
Miller, et al., “Long-term follow-up of patients with fulminant Clostridium difficile colitis,” J. Gastrointest. Surg., 13(5):956-959 (2009). [cited by applicant]
Miller, et al., “Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals,” Infect Control Hosp Epidemiol., 23(3):137-40 (2002). [cited by applicant]
Miller, “The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy,” Anaerobe, 15(6):281-284 (2009). [cited by applicant]
Minami, et al., “Effects of lipopolysaccharides and chelator onmercury content in the cerebrum of thimerosal administered mice,” Environmental Toxicology and Pharmacology, 24:316-320 (2007). [cited by applicant]
Minami, et al., “Roles of nitric oxide prostaglandins in the increased permeability of the blood-brain barrier caused by lipopolysaccharide,” Environmental Toxicology and Pharmacology, 5:35-41 (1998). [cited by applicant]
Moayyedi, et al., “Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial,” Gastroenterology, 149(1):102-9 (2015). [cited by applicant]
Molecular Studies in Autism, 2004 Funding Cycle, Cure Autism Now, Cure Autism Now Foundation, pp. 1-7 (2005) www.cureautismnow.org. [cited by applicant]
Molloy & Manning-Courtney, “Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders,”Autism 7(2):165-171 (2003). [cited by applicant]
Momose, et al., “16S rRNA gene sequence-based analysis of clostridia related to conversion of germfree mice to the normal state,” Journal of Applied Microbiology, 107:2088-2097 (2009). [cited by applicant]
Morris, et al., “Clostridium difficile Colitis: An Increasingly Aggressive Iatrogenic Disease?” Arch Surg., 137(10):1096-1100 (2002). [cited by applicant]
Mucosal immunity: homeostasis (WS-064): Chairpersons: Toshiaki Ohteki, Makoto Iwata, International Immunology, 22:Suppl 1 Pt. 3, 1-9 (2010). [cited by applicant]
Mullard, “Microbiology: The Inside Story,” Nature, 453:578-580 (2008). [cited by applicant]
Mulloy, et al., “Gluten-free and casein-free diets in the treatment of autism spectrum disorders: A systematic review,” Research in Autism Spectrum Disorders, 4:328-339 (2010). [cited by applicant]
Murai, et al., “Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis,” Nat Immunol., pp. 1-20 (2009). [cited by applicant]
Mutaflor, “Brief Summary of Therapeutic Principles,” Ardeypharm GmbH 0796 D-58313 Herdecke Germany, 6 pgs (2006). [cited by applicant]
Mutaflor, “For Functional and Inflammatory Bowel Diseases for Extraintestinal Manifestations for Activation of the Body's In-Built Defences,” Ardeypharm GmbH 0796, D-58313 Herdecke Germany, 8 pgs (2006). [cited by applicant]
Mutaflor, “Safety of Therapy,” Ardeypharm GmbH 0796, D-58313 Herdecke Germany, 4 pgs (1988). [cited by applicant]
Muto, et al., “A Large Outbreak of Clostridium difficile-Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use,” Infect Control Hosp Ep… [cited by applicant]
Niehus & Lord, “Early Medical History of Children with Autism Spectrum Disorders,” Journal of Developmental Behavioral Pediatrics, 27(2):S120-S127 (2006). [cited by applicant]
Niu, et al., “Prevalence and Impact of Bacteriophages on the Presence of [cited by applicant]
O'Hara, et al., “The gut flora as a forgotten organ,” EMBO Rep., 7(7):688-693 (2006). [cited by applicant]
O'Brien, et al., “The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences,” Infect Control Hosp Epidemiol., 28(11):1219-27 (2007). [cited by applicant]
Ochoa-Reparaz, et al., “Gut, Bugs, and Brain: Role of Commensal Bacteria in the Control of Central Nervous System Disease”, Annals Neurology, 69:240-247 (2011). [cited by applicant]
O'Connor, et al., “Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain,” Gastroenterology, 136(6):1913-1924 (2009). [cited by applicant]